This Article Full Text Full Text (PDF) All Versions of this Article: 46/4/953    most recent 01.HYP.0000174601.30793.b1v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Elased, K. M. Articles by Morris, M. Search for Related Content PubMed PubMed Citation Articles by Elased, K. M. Articles by Morris, M.

(Hypertension. 2005;46:953.)
© 2005 American Heart Association, Inc.

Part 2 Original Articles

Novel Mass Spectrometric Methods for Evaluation of Plasma Angiotensin Converting Enzyme 1 and Renin Activity

From Wright State University School of Medicine, Department of Pharmacology and Toxicology, Dayton, Ohio.

Correspondence to Khalid M. Elased, RPh, PhD, Wright State University School of Medicine, 207 Health Science Bldg, Department of Pharmacology and Toxicology, 3640 Colonel Glen Hwy, Dayton, OH 45435. E-mail Khalid.elased{at}wright.edu

This article demonstrates the applicability of quantitative proteomics to assays of proteolytic enzyme activity. A novel assay was developed for measurement of renin and angiotensin-converting enzyme (ACE) activity in plasma. The method was validated in animal models associated with alterations of the renin angiotensin system (RAS). Using surface-enhanced laser desorption/ionization time of flight mass spectrometry (SELDI-TOF-MS) with a ProteinChip Array technology, plasma renin and ACE1 could be measured in <0.5 µL of plasma. Plasma is incubated with peptide substrates for renin and ACE, tetradecapeptide (TDP), and angiotensin I (Ang I), respectively. The reactions mixtures are spotted onto the ProteinChip WCX2 and detected using SELDI-TOF-MS. Peak height or area under curve for TDP, Ang I, and angiotensin II (Ang II) peaks are measured. There was a linear relationship between disappearance of substrate and appearance of products for both renin and ACE (R²=0.95 to 0.98). ACE1 activity was blocked with chelating agents (EDTA and 1,10 phenanthrolene), indicating action of a metalloprotease. The ACE1 inhibitor, captopril, selectively blocked ACE1. Renin activity was specifically blocked with renin inhibitor and was not affected by phenanthrolene or captopril. Animal models tested were Ang AT1a receptor-deficient and streptozotocin (STZ) diabetic mice. Plasma renin activity was increased >2-fold in AT1a^–/– as compared with AT1a^+/+. In STZ diabetic mice, ACE1 was increased 2-fold as compared with controls. The advantage of the method is that it is tagless, does not require additional purification steps, and is extremely sensitive. The approach can be multiplexed and used for identification of novel substrates/inhibitors of the RAS.

Key Words: angiotensin • angiotensin-converting enzyme • captopril • hypertension • renin

This article has been cited by other articles:

				S. Belmadani, M. Zerfaoui, H. A. Boulares, D. I. Palen, and K. Matrougui Microvessel vascular smooth muscle cells contribute to collagen type I deposition through ERK1/2 MAP kinase, {alpha}v{beta}3-integrin, and TGF-{beta}1 in response to ANG II and high glucose Am J Physiol Heart Circ Physiol, July 1, 2008; 295(1): H69 - H76. [Abstract] [Full Text] [PDF]

				V. Farah, K. M. Elased, and M. Morris Genetic and dietary interactions: role of angiotensin AT1a receptors in response to a high-fructose diet Am J Physiol Heart Circ Physiol, August 1, 2007; 293(2): H1083 - H1089. [Abstract] [Full Text] [PDF]

				R. B. Wichi, V. Farah, Y. Chen, M. C. Irigoyen, and M. Morris Deficiency in angiotensin AT1a receptors prevents diabetes-induced hypertension Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2007; 292(3): R1184 - R1189. [Abstract] [Full Text] [PDF]